Loading...
XNYSNVS
Market cap189bUSD
Dec 20, Last price  
97.11USD
1D
0.35%
1Q
-16.24%
Jan 2017
48.85%
Name

Novartis AG

Chart & Performance

D1W1MN
XNYS:NVS chart
P/E
12.79
P/S
4.07
EPS
7.59
Div Yield, %
3.82%
Shrs. gr., 5y
-2.25%
Rev. gr., 5y
-2.58%
Revenues
46.66b
-9.97%
28,247,000,00032,526,000,00036,749,000,00038,947,000,00042,584,000,00045,103,000,00051,561,000,00059,375,000,00057,561,000,00058,831,000,00053,634,000,00050,387,000,00049,436,000,00050,135,000,00053,166,000,00048,677,000,00049,898,000,00052,877,000,00051,828,000,00046,660,000,000
Net income
14.85b
+113.52%
5,767,000,0006,130,000,0007,175,000,00011,946,000,0008,195,000,0008,400,000,0009,794,000,0009,113,000,0009,505,000,0009,175,000,00010,210,000,00017,783,000,0006,712,000,0007,703,000,00012,611,000,0007,147,000,0008,072,000,00024,021,000,0006,955,000,00014,850,000,000
CFO
14.46b
+1.56%
6,725,000,0008,080,000,0008,710,000,0009,210,000,0009,769,000,00012,191,000,00014,067,000,00014,309,000,00014,194,000,00013,174,000,00013,897,000,00011,897,000,00011,475,000,00012,621,000,00014,272,000,00013,625,000,00013,650,000,00015,071,000,00014,236,000,00014,458,000,000
Dividend
Sep 24, 20243.77721 USD/sh
Earnings
Jan 31, 2025

Profile

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
URL
https://www.novartis.com/
IPO date
May 07, 2001
Employees
103,000
Domiciled in
CH
Incorporated in
CH

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
46,660,000
-9.97%
51,828,000
-1.98%
52,877,000
5.97%
Cost of revenue
23,843,000
25,482,000
25,407,000
Unusual Expense (Income)
NOPBT
22,817,000
26,346,000
27,470,000
NOPBT Margin
48.90%
50.83%
51.95%
Operating Taxes
551,000
1,416,000
2,119,000
Tax Rate
2.41%
5.37%
7.71%
NOPAT
22,266,000
24,930,000
25,351,000
Net income
14,850,000
113.52%
6,955,000
-71.05%
24,021,000
197.58%
Dividends
(7,255,000)
(7,506,000)
(7,368,000)
Dividend yield
4.09%
4.09%
4.06%
Proceeds from repurchase of equity
(8,719,000)
(10,552,000)
(3,004,000)
BB yield
4.91%
5.75%
1.66%
Debt
Debt current
6,314,000
6,182,000
6,570,000
Long-term debt
21,862,000
23,571,000
26,419,000
Deferred revenue
4,697,000
Other long-term liabilities
4,523,000
4,906,000
1,475,000
Net debt
12,387,000
8,269,000
1,419,000
Cash flow
Cash from operating activities
14,458,000
14,236,000
15,071,000
CAPEX
(2,753,000)
(2,671,000)
(2,971,000)
Cash from investing activities
5,596,000
1,468,000
4,208,000
Cash from financing activities
(14,278,000)
(20,562,000)
(16,264,000)
FCF
23,537,000
25,841,000
26,184,000
Balance
Cash
13,962,000
18,930,000
28,329,000
Long term investments
1,827,000
2,554,000
3,241,000
Excess cash
13,456,000
18,892,600
28,926,150
Stockholders' equity
46,791,000
123,055,000
138,859,000
Invested Capital
64,165,000
70,867,400
73,745,850
ROIC
32.98%
34.48%
33.50%
ROCE
28.57%
28.50%
25.98%
EV
Common stock shares outstanding
2,092,000
2,197,000
2,260,000
Price
84.87
1.53%
83.59
4.12%
80.28
-4.03%
Market cap
177,548,040
-3.32%
183,647,221
1.22%
181,432,798
-5.53%
EV
190,018,040
191,997,221
183,018,798
EBITDA
31,094,000
33,527,000
33,583,000
EV/EBITDA
6.11
5.73
5.45
Interest
855,000
837,000
811,000
Interest/NOPBT
3.75%
3.18%
2.95%